Aberrant Expression of Bone Morphogenetic Proteins in the Disease Progression and Metastasis of Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jun 19

PMID 37333824

Authors

Ming Liu

Laijian Sui

Ziqian Fang

Wen G Jiang

Lin Ye

Affiliations

Soon will be listed here.

Abstract

Background: Bone morphogenetic proteins (BMPs) play crucial roles in the tumorigenesis and metastasis of cancers. Controversy remains about the exact implications of BMPs and their antagonists in breast cancer (BC), due to their diverse and complex biological functions and signalling. A comprehensive study of the whole family and their signalling in breast cancer is provoked.

Methods: Aberrant expression of BMP, BMP receptors and antagonists in primary tumours in breast cancer were analysed by using TCGA-BRCA and E-MTAB-6703 cohorts. Related biomarkers including ER, HER, proliferation, invasion, angiogenesis, lymphangiogenesis and bone metastasis were involved to identify the relationship with BMPs in breast cancer.

Results: The present study showed BMP8B was significantly increased in breast tumours, while BMP6 and ACVRL1 were decreased in breast cancer tissues. The expressions of BMP2, BMP6, TGFBR1 and GREM1 were significantly correlated with BC patients' poor overall survival. Aberrant expression of BMPs, together with BMP receptors, were explored in different subtypes of breast cancer according to ER, PR and HER2 status. Furthermore, higher levels of BMP2, BMP6 and GDF5 were revealed in triple negative breast cancer (TNBC) whilst BMP4, GDF15, ACVR1B, ACVR2B and BMPR1B were relatively higher in Luminal type BC. ACVR1B and BMPR1B were positively correlated with ERα but were inversely correlated with ERβ. High expression of GDF15, BMP4 and ACVR1B were associated with poorer overall survival in HER2 positive BC. BMPs also play dual roles in tumour growth and metastasis of BC.

Conclusion: A shift pattern of BMPs was showed in different subtypes of breast cancer suggesting a subtype specific involvement. It provokes more research to shed light on the exact role of these BMPs and receptors in the disease progression and distant metastasis through a regulation of proliferation, invasion and EMT.

Citing Articles

Molecular mechanism of bone metastasis in breast cancer.

Sui L, Wang J, Jiang W, Song X, Ye L Front Oncol. 2024; 14:1401113.

PMID: 39605887 PMC: 11599183. DOI: 10.3389/fonc.2024.1401113.

p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway.

Wang M, Zhong L, Zhang H, Wan P, Chu X, Shao X Med Oncol. 2024; 41(7):166.

PMID: 38819709 DOI: 10.1007/s12032-024-02398-2.

BMP Stimulation Differentially Affects Phosphorylation and Protein Stability of β-Catenin in Breast Cancer Cell Lines.

Ilhan M, Hastar N, Kampfrath B, Spierling D, Jatzlau J, Knaus P Int J Mol Sci. 2024; 25(9).

PMID: 38731813 PMC: 11083028. DOI: 10.3390/ijms25094593.

Unraveling the Molecular Complexity of Adenoid Cystic Carcinoma (ACC): A Comprehensive Exploration of Hub Genes, Protein-Protein Interaction (PPI) Networks, microRNA (miRNA) Involvement, and Drug-Gene Interactions (DGIs).

Karri R, Bojji M, Rudraraju A, Mohammad A, Kosuru V, Kalisipudi S Cureus. 2024; 16(2):e54730.

PMID: 38524085 PMC: 10961157. DOI: 10.7759/cureus.54730.

Loss of Delays Mammary Tumor Development and Impairs Metastasis.

Simpson K, Staikos C, Watson K, Moorehead R Int J Mol Sci. 2023; 24(18).

PMID: 37762032 PMC: 10530983. DOI: 10.3390/ijms241813730.

References

Zhang G, Huang P, Chen A, He W, Li Z, Liu G . How BMP-2 induces EMT and breast cancer stemness through Rb and CD44?. Cell Death Dis. 2018; 9(2):20. PMC: 5833867. DOI: 10.1038/s41419-017-0037-0. View

Vohra P, Buelow B, Chen Y, Serrano M, Vohra M, Berry A . Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study. Cancer Cytopathol. 2016; 124(11):828-835. DOI: 10.1002/cncy.21745. View

Raida M, Clement J, Leek R, Ameri K, Bicknell R, Niederwieser D . Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005; 131(11):741-50. DOI: 10.1007/s00432-005-0024-1. View

Chi L, Burrows A, Anderson R . Bone morphogenetic protein signaling in breast cancer progression. Growth Factors. 2019; 37(1-2):12-28. DOI: 10.1080/08977194.2019.1626378. View

Ye L, Lewis-Russell J, Davies G, Sanders A, Kynaston H, Jiang W . Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 2007; 30(2):521-9. View

Wang K, Sun X, Feng H, Fei C, Zhang Y . DNALK2 inhibits the proliferation and invasiveness of breast cancer MDA-MB-231 cells through the Smad-dependent pathway. Oncol Rep. 2017; 37(2):879-886. DOI: 10.3892/or.2016.5343. View

Park S, Sung N, Choi B, Kim W, Kim S, Surh Y . Gremlin-1 augments the oestrogen-related receptor α signalling through EGFR activation: implications for the progression of breast cancer. Br J Cancer. 2020; 123(6):988-999. PMC: 7493948. DOI: 10.1038/s41416-020-0945-0. View

Karaman S, Detmar M . Mechanisms of lymphatic metastasis. J Clin Invest. 2014; 124(3):922-8. PMC: 3938272. DOI: 10.1172/JCI71606. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

10.

Lian W, Liu G, Liu Y, Zhao Z, Yi T, Zhou H . Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer. Oncol Rep. 2013; 30(1):193-200. DOI: 10.3892/or.2013.2462. View

11.

Ampuja M, Jokimaki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo E, Kallioniemi A . BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer. 2013; 13:429. PMC: 3848934. DOI: 10.1186/1471-2407-13-429. View

12.

Sun Z, Cai S, Zabkiewicz C, Liu C, Ye L . Bone morphogenetic proteins mediate crosstalk between cancer cells and the tumour microenvironment at primary tumours and metastases (Review). Int J Oncol. 2020; 56(6):1335-1351. DOI: 10.3892/ijo.2020.5030. View

13.

Huang T, Wu Q, Huang H, Zhang C, Wang L, Wang L . Expression of GALNT8 and O-glycosylation of BMP receptor 1A suppress breast cancer cell proliferation by upregulating ERα levels. Biochim Biophys Acta Gen Subj. 2021; 1866(1):130046. DOI: 10.1016/j.bbagen.2021.130046. View

14.

Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi O, Elenius K . Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):259-68. DOI: 10.1007/s10911-008-9079-3. View

15.

Ketolainen J, Alarmo E, Tuominen V, Kallioniemi A . Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat. 2010; 124(2):377-86. DOI: 10.1007/s10549-010-0808-0. View

16.

Safina A, Vandette E, Bakin A . ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene. 2006; 26(17):2407-22. DOI: 10.1038/sj.onc.1210046. View

17.

Du J, Yang S, Wang Z, Zhai C, Yuan W, Lei R . Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways. J Cell Biochem. 2007; 103(5):1584-97. DOI: 10.1002/jcb.21547. View

18.

Flores-Perez A, Marchat L, Rodriguez-Cuevas S, Bautista-Pina V, Hidalgo-Miranda A, Arechaga Ocampo E . Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer. Sci Rep. 2016; 6:34504. PMC: 5050489. DOI: 10.1038/srep34504. View

19.

Chen Y, Wu C, Chen J, Tsai C, Wu C, Chang P . Diltiazem inhibits breast cancer metastasis via mediating growth differentiation factor 15 and epithelial-mesenchymal transition. Oncogenesis. 2022; 11(1):48. PMC: 9376069. DOI: 10.1038/s41389-022-00423-5. View

20.

Paiva C, Serrano S, Paiva B, Scapulatempo-Neto C, Soares F, Rogatto S . Absence of TGF-βRII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors. Cancer Biomark. 2012; 11(5):209-17. DOI: 10.3233/CBM-2012-00281. View